
iGlarLixi treatment significantly boosts time in range (TIR) and reduces time above range (TAR) in type 2 diabetes patients. In this 16-week study, 124 insulin-naive adults (mean age 55.6, HbA1c 10.2%) receiving ≥2 OADs saw TIR increase by 26.2%, mean blood glucose decrease by 52.5 mg/dL, postprandial glucose drop by 73.7 mg/dL, and TAR reduced by 28.7%. Minimal hypoglycemia (1.4 level 1 events and 0.6 level 2 events per person-year) was reported.
Like
Save
Share